Cabozantinib, nivolumab, and ipilimumab combination therapy have demonstrated significant progression-free survival benefits in previously untreated, advanced renal-cell carcinoma patients with intermediate or poor prognostic risk.

A phase 3 double-blind trial that enrolled 855 patients with advanced clear-cell renal-cell carcinoma who had not received prior treatment and had intermediate or poor prognostic risk randomized them into two groups: the experimental group (40 mg of cabozantinib along with nivolumab and ipilimumab daily), and the control group (matched placebo with nivolumab and ipilimumab).

The experimental group exhibited a higher progression-free survival probability at 12 months and a higher response rate compared to the control group. However, grade 3 or 4 adverse events were more common in the experimental group than in the control group.

Hence, the combination of Cabozantinib, nivolumab, and ipilimumab can potentially treat advanced renal-cell carcinoma patients who have not received treatment before and have intermediate or poor prognostic risk.

REFERENCE-

Choueiri TK, Powles T, Albiges L, et al. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. N Engl J Med 2023; 388:1767-1778. DOI: 10.1056/NEJMoa2212851